迈克尔·高伟：中国医药生物产业正进入黄金发展阶段
深圳市美博免费白菜中心首页投资有限公司总裁迈克尔·高伟 (Michael Garvey) 日前在接受新华社记者专访时表示，中国医药生物产业正从更多的临床阶段过渡到更多的商业阶段，应多关注中国市场。
“过去十年，中国在医疗产业已经实现了指数增长，未来将会持续进行扩张。但市场的增长需要一个前提，那就是必须有供应链的商业化才可以实现，而如何实现供应链的商业化，弥补供需之间的巨大差异，就是我们努力的方向。”高伟表示。
高伟对记者说，通过公司对中国市场的研究数据，十分坚定地看好中国市场发展潜力。“中国有相当多的医药生物产业可以服务于全球市场，很大程度上是一个增长市场，正处于从临床阶段向商业阶段，国内商业向全球商业过渡的关键阶段。”
这家位于深圳的生物医药开发制造企业成立于2016年，以引进国际前沿生物医药技术和产品为核心，打造集检测、医药、医疗为一体的生命科技生态、世界级医疗健康科技企业。今年8月，高伟被任命为该公司的总经理，此前拥有超过20年的国际生物技术和CDMO经验，曾在美国、亚洲和欧洲的生物制药企业担任管理职务。曾在三星生物制药公司（Samsung Biologics)担任创始执行委员和副总裁，负责为设计、验证、技术转让、运营工作提供支持，并成功地为单个运营点的最大药品生产设施（产能为362000L）引入超过14种新药。
“当我与创始人刘如银交谈时，发现我们有共同的愿景和目标，就是为全世界所有人提供并解决临床上未被满足的医疗需求，让人们都能获得非常便宜的药物和相关配套服务，甚至可以提供一些免费的药物。”高伟说。
“我看到中国有14亿人口，我愿意帮助和发展这个市场，并在其中发展下一代生物技术。”高伟表示。
当问及如何看待医药产业在粤港澳大湾区发展时，高伟表示，粤港澳大湾区是一个增长非常快的市场。“但我认为我们需要在大湾区寻找一些突破点，目前，医药生物企业所面对的竞争环境变得越来越动态化，企业要发挥自身优势，建立协作型竞争战略，共同营造良好的协作环境。”
高伟相信，中国很有可能在未来五年里成为医疗行业最大的国家，乐土生命也将跨越国境进入美国市场乃至全球市场，努力成为世界最大的CDMO企业。
Interview: China to lead and become largest market in global medical industry in next 5 yrs, says CLB president
Abstract : China’s biomedical industry is transiting from the more clinical stage into a more commercial stage, and Cheerland is now at a critical phase in China and will attach more importance to the Chinese market, Michael Garvey, Managing Director and President of Cheerland Biotechnology (CLB) said.
Michael Garvey, Managing Director of the Board, President of Cheerland Biotechnology (CLB) speaks during an interview in Shenzhen, south China’s Guangdong Province, Oct. 15, 2021.
BEIJING, Oct. 19 (Xinhua) — China’s biomedical industry is transiting from the more clinical stage into a more commercial stage, and Cheerland is now at a critical phase in China and will attach more importance to the Chinese market, Michael Garvey, Managing Director of the Board, President of Cheerland Biotechnology (CLB), told Xinhua at an interview in Shenzhen.
Garvey places high hopes on the Chinese market, as he said that China is expected to taking the lead and become the largest market in the world medical industry in the next five years, and Cheerland, a cutting-edge biotech developer based in Shenzhen of south China’s Guangdong province, would take the advantage of Chinese market and expand businesses into the United States or even Europe to developing into the most vigorous CDMO enterprises in the world.
To facilitate Chinese medical industry’s supply chain to attain a faster growth, Cheerland is helping to commercialize China’s the supply chain and balance the difference between demand and supply, according to Garvey.
Data from Cheerland’s marketing house shows the company’s optimistic view about potential Chinese market in biomedical industry. Garvey added that China has a superb biology economic value to the global market, and it is a very fast growing market.
Garvey said he upholded a philosophy to fulfill unmet medical needs to all people across the world, and provide access to all people to affordable medicines and supporting facilities, or even some medicines will do for free.
Mentioning China with a huge population of 1.4 billion, he would try to help foster the Chinese market and develop the next generation biotech technology within China, Garvey told Xinhua.
“China’s Guangdong-Hong Kong-Macau Greater Bay Area is a very growth market, but I think some of our barriers that we need to look in the Greater Bay Area is how can we take it from a competitive advantage across companies to a collaborative environment,” said Garvey.
With 25 years of experiences in international biotech & CDMO, Michael Garvey held various executive, technical, and operational leadership positions in biopharmaceutical companies in the Unite States, Asia, and Europe, who also served as Global Head of Technical Operations, BeiGene; a founding Executive member and Vice President of Samsung Biologics Manufacturing, where he helped design, validate, technology transfer, operate, and successfully licensed an impressive over 14 novel medicines in the largest Drug Substance facility (362,000L of capacity) in a single location.
Founded in 2016, the CLB aims to build a world-class biotech enterprise, offering a wide array of products and services, ranging from diagnoses, pharmaceuticals, and healthcare services.
(Contributed by Mao Lili, Li Yan, edited by Jiang Feifan with Xinhua Silk Road)
